SPINOGENIX
Spinogenix is a developer of a new class of therapeutics for neurodegenerative and psychiatric diseases. The company is focused on regenerating synapses to reverse declines in cognitive and motor function. They envision the use of SPGs as a monotherapy or in combination with other therapeutics that target disease-specific degenerative processes. Spinogenix's mission is to create transformative therapeutics for diseases involving synaptic loss and dysfunction. It was founded in 2016 and is headquartered in San Diego, California.
SPINOGENIX
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2016-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.spinogenix.com
Total Employee:
1+
Status:
Active
Contact:
858-263-3252
Total Funding:
14.41 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Font Awesome Global Site Tag ReCAPTCHA Organization Schema
Similar Organizations
Anagin
Anagin is developing first-in-class therapies for treating neuropsychiatric diseases.
Clene Nanomedicine
Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
Convalesce
Stem Cell Based Therapy for Neurodegenerative diseases
Enleofen Bio Pte Ltd
Enleofen is a developer of bio technology designed for the treatment of fibro-inflammatory diseases.
ImmunoForge
ImmunoForge is a developer of a new drug intended for treating sarcopenia and cancer.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Vivreon Biosciences
Vivreon Biosciences is developing a new class of small molecule therapeutics for the treatment of chronic diseases.
Current Employees Featured
Founder
Investors List
U.S. Department of Defense
U.S. Department of Defense investment in Grant - Spinogenix
National Institutes of Health
National Institutes of Health investment in Grant - Spinogenix
Official Site Inspections
http://www.spinogenix.com Semrush global rank: 4.21 M Semrush visits lastest month: 2.37 K
- Host name: 138.197.229.35
- IP address: 138.197.229.35
- Location: North Bergen United States
- Latitude: 40.793
- Longitude: -74.0247
- Metro Code: 501
- Timezone: America/New_York
- Postal: 07047
More informations about "Spinogenix"
Spinogenix is pioneering therapeutics that restore synapses to …
Spinogenix’s first-in-human Phase 1/2 study in Australia is fully enrolled and not recruiting. Alzheimer’s Disease The Australia Human Research Ethics Committees has approved the …See details»
Spinogenix - Crunchbase Company Profile & Funding
Organization. Spinogenix . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Spinogenix's mission is to create transformative therapeutics for diseases involving synaptic …See details»
Team - Spinogenix
Team Executive Team Stella Sarraf, PhD CEO, Founder, DirectorSEE BIO Peter Vanderklish, PhD Chief Science OfficerSEE BIO Craig Erickson, MD Chief Medical AdvisorSEE BIO …See details»
Spinogenix, Inc. - LinkedIn
Spinogenix, Inc. | 982 followers on LinkedIn. Developing a new class of therapeutics for neurodegenerative and psychiatric diseases | Who we are In most neurodegenerative diseases we lose ...See details»
Companies To Watch: Spinogenix - lifescienceleader.com
Oct 18, 2024 Spinogenix has benefited from close collaboration with academic institutions and has used grant funding to de-risk the company, says Sarraf. “All of our animal work was done …See details»
Clinical Trials - Spinogenix
Spinogenix strongly urges you to seek professional medical advice and guidance as to legal, safe and approved treatments for your disease. Alzheimer's Disease We are currently recruiting for …See details»
Spinogenix Company Profile - Office Locations, Competitors
Spinogenix is a company that provides therapeutics restoring the brain connections and functions lost in brain injury and neurodegenerative diseases. It is engaged in the development of drugs …See details»
Spinogenix - Funding, Financials, Valuation & Investors - Crunchbase
Spinogenix is a developer of a new class of therapeutics for neurodegenerative and psychiatric diseases. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
Spinogenix, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Jul 5, 2023 Spinogenix Contact [email protected] Media Contact Kristin Politi, Ph.D.LifeSci [email protected](646) 876-4783 . Phase 2 Orphan Drug. 100 Deals …See details»
FDA grants IND clearance for Spinogenix’s ALS …
May 30, 2024 Spinogenix CEO and founder Stella Sarraf said: “Having completed the Phase I safety study in healthy subjects in Australia, we are thrilled to have gained FDA acceptance of our US IND for SPG302 in ALS. …See details»
Spinogenix Announces FDA Clearance of IND Application for …
May 29, 2024 Spinogenix’s new approach works at the synaptic level to regenerate synapses. This first study in people with ALS is an important step towards determining whether SPG302 …See details»
Spinogenix Awarded $3 Million NIH Grant to Support
Sep 12, 2023 Spinogenix was founded in 2016 with the mission to develop transformative therapeutics for diseases involving synaptic loss and dysfunction. Our drugs are designed to …See details»
Science - Spinogenix
SCIENCE Treatments for diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), schizophrenia, glaucoma, and Fragile X syndrome (FXS) leave a critical gap in effective …See details»
Spinogenix Granted FDA Orphan Drug Designation for SPG302
Jun 7, 2021 Spinogenix was founded in 2016 with the mission to develop transformative therapeutics for diseases involving synaptic loss and dysfunction. Our drugs are designed to …See details»
Synapse-Generating Small Molecule for ALS Receives Nod from …
May 30, 2024 The Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SPG302 (Spinogenix, San Diego, CA) for evaluatio. The Neurology …See details»
Spinogenix Announces U.S. FDA Approval of its Investigational …
Apr 15, 2024 Spinogenix, Inc. SPG601 is a once-a-day pill that works by restoring synaptic function to address core symptoms of Fragile X Syndrome. SAN DIEGO, April 15, 2024 …See details»
Spinogenix Announces Approval from the Australia Human
Jun 20, 2024 Spinogenix is dedicated to developing transformative therapeutics for conditions involving the loss or dysfunction of synapses. Our lead clinical-stage synaptic regenerative …See details»
Spinogenix Announces Enrollment is Open for its Phase 2 Clinical …
Jul 23, 2024 Spinogenix, Inc. U.S. FDA has granted Orphan Drug Designation to SPG601 for the Treatment of Fragile X Syndrome. SPG601 is a novel small molecule that works by …See details»
Synapse-restoring pill set for human trials as novel schizophrenia ...
Sep 26, 2024 Spinogenix, the company behind the once-a-day pill that restored lost nerve cell connections in people with amyotrophic lateral sclerosis (ALS), has now set its sights on using …See details»
News - Spinogenix
Spinogenix’s Daily Pill SPG302 Receives FDA IND Nod for ALS Treatment. A Promising Treatment for MND. A new drug that could reverse the worst symptoms of MND is about to be …See details»